SCHEMBL15035567

SCHEMBL15035567

CCOc1cc2cnc(Nc3ccc(NC4CCN(C)CC4)cc3)nc2n(C2C(=O)c3ccccc3N(C)C2(C)C)c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 9/20 0.43
CDK4 P11802 6/20 0.42
CCND1 P24385 6/20 0.42
FGFR1 P11362 5/20 0.42
FGFR2 P21802 2/20 0.42
FGFR4 P22455 2/20 0.42
FGFR3 P22607 2/20 0.42
CCNA2 P20248 4/20 0.40
CDK2 P24941 4/20 0.40
CCND2 P30279 3/20 0.38
CCND3 P30281 3/20 0.38
PDGFRB P09619 2/20 0.38
SRC P12931 2/20 0.38
PDGFRA P16234 1/20 0.38
CCNE1 P24864 3/20 0.38
CDK1 P06493 2/20 0.38
CCNB1 P14635 2/20 0.38
MAPK7 Q13164 1/20 0.38
PIK3CD O00329 1/20 0.38
PRKAB2 O43741 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15035465 0.81 CDK4 (0.44) TNK2CDK4CCND1FGFR1FGFR2
SCHEMBL15035327 0.81 CCND1 (0.44) TNK2CDK4CCND1FGFR1FGFR2
SCHEMBL15041552 0.80 CDK4 (0.49) TNK2CDK4CCND1FGFR1FGFR2
SCHEMBL15035364 0.80 CDK4 (0.46) TNK2CDK4CCND1FGFR1FGFR2
SCHEMBL15035480 0.80 CDK4 (0.38) CDK4CCND1FGFR1FGFR2FGFR4
SCHEMBL15041574 0.76 CDK4 (0.51) TNK2CDK4CCND1FGFR1FGFR2
SCHEMBL15035337 0.76 CDK4 (0.51) TNK2CDK4CCND1FGFR1FGFR2
SCHEMBL15035587 0.74 JAK3 (0.44) TNK2CDK4CCND1FGFR1FGFR2
SCHEMBL15035305 0.74 CDK4 (0.48) TNK2CDK4CCND1FGFR1FGFR2
SCHEMBL15035545 0.74 MAP4K1 (0.45) TNK2CDK4CCND1FGFR1FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 TNK2 7/4885CDK4 404/4885CCND1 2153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.